Neurocrine Biosciences (NBIX) : Baker Bros. Advisors Lp scooped up 44,683 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 895,422 shares of Neurocrine Biosciences which is valued at $43,320,516.Neurocrine Biosciences makes up approximately 0.48% of Baker Bros. Advisors Lp’s portfolio.
Other Hedge Funds, Including , Rock Springs Capital Management Lp boosted its stake in NBIX in the latest quarter, The investment management firm added 5,000 additional shares and now holds a total of 409,500 shares of Neurocrine Biosciences which is valued at $19,811,610. Neurocrine Biosciences makes up approx 1.39% of Rock Springs Capital Management Lp’s portfolio. Ghost Tree Capital added NBIX to its portfolio by purchasing 125,000 company shares during the most recent quarter which is valued at $6,047,500. Neurocrine Biosciences makes up approx 2.49% of Ghost Tree Capital’s portfolio. Pacer Advisors added NBIX to its portfolio by purchasing 6,256 company shares during the most recent quarter which is valued at $302,665. Neurocrine Biosciences makes up approx 0.05% of Pacer Advisors’s portfolio.Candriam Luxembourg S.c.a. reduced its stake in NBIX by selling 2,700 shares or 2.27% in the most recent quarter. The Hedge Fund company now holds 116,300 shares of NBIX which is valued at $5,910,366. Neurocrine Biosciences makes up approx 0.15% of Candriam Luxembourg S.c.a.’s portfolio.
Neurocrine Biosciences opened for trading at $48.63 and hit $50.28 on the upside on Thursday, eventually ending the session at $50.12, with a gain of 3.43% or 1.66 points. The heightened volatility saw the trading volume jump to 5,68,942 shares. Company has a market cap of $4,348 M.
On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.
Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.